ERSEUS 1996 was an investment program established in 1996 with $35 million in capital commitments to invest in undervalued and growth equity transactions. This fund is fully invested.

PERSEUS CAPITAL, L.L.C. was established in 1997 with $102 million in capital commitments with a focus on growth equity investments and some venture opportunities. This fund is fully invested.

PERSEUS ACQUISITION/RECAPITALIZATION FUND, L.L.C., a co-investment/club fund, was established in 1999 to participate in larger growth equity, buyout, and recapitalization transactions of operating companies, frequently alongside other Perseus funds. This fund, which called $98 million in capital commitments from investors, has reached its termination date and is no longer making investments.

PERSEUS 2000, L.L.C. was established in 2000 with $222 million in capital commitments to focus on undervalued growth equity, small buyout, and venture opportunities mainly in the energy, environmental, and engineering technology industries and healthcare sectors. This fund is fully invested.

PERSEUS MARKET OPPORTUNITY FUND, L.P. was established in 2002 with $340 million of committed capital to pursue control investments in undervalued growth equity companies and turnaround situations. This fund is fully invested.

PERSEUS 2000 EXPANSION, L.L.C., which was established in 2004, is a $153 million fund used primarily for follow-on energy, environmental, and engineering technology investments for Perseus 2000 and other small growth equity transactions. This fund is fully invested.

PERSEUS PARTNERS VII, L.P., established in 2006, is a $602 million fund focused on control investments in middle market growth equity transactions principally in the following industries: energy, environmental, and engineering technologies; healthcare; and branded consumer products. This fund has been fully committed or reserved.

PERSEUS-SOROS BIOPHARMACEUTICAL FUND, LP, which was established in 2000 with $449 million in capital commitments, focused on investments in life science companies developing biopharmaceutical products and/or creating businesses based on advanced life science technologies. This fund is managed by a separate executive team, the senior executives of which were recruited at the time of the fund’s formation by Perseus and its co-manager. This fund is fully invested.

Updated 11/10/11